Recent

% | $
Quotes you view appear here for quick access.

CEL-SCI Corporation Message Board

yankeesnyc27 210 posts  |  Last Activity: Apr 21, 2016 3:46 PM Member since: Nov 7, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • yankeesnyc27 yankeesnyc27 Apr 21, 2016 3:46 PM Flag

    hey c assa sandra..... "That a tiny sample of 17 ".... The official Hungarian report say 19, NOT 17 !
    If YOU see 17 and every one else sees 19, maybe you have a reading comprehension problem, among others/

    Does the FDA care about the 14 year old P2??
    **YOU do , they don't.**
    Again, YOU see P2 has something to continue to beat to death.
    The FDA doesn't

    ***EVERYONE IS WRONG, and one person ,YOU, is right????

    "since IL-2-rtreated H&N tumors always recur? "

    IL and MK are NOT the same !
    What is YOUR VERIFIABLE source for YOUR DISINFORMATION???

    Does the FDA evaluate MEDS OR institutional ownership???

    What did the Israeli P2 ( per JAMA ) reveal??

    Sentiment: Strong Buy

  • 17,19,21, P2 & P3.
    He has MANY times posted information from a H&N study done at the University of Turin , that was not a P1 , P2 , or P3 clinical trial and that involved using IL.
    He reported results from that study ( 1992 ? ) and MISREPRESENTED it as being relevant to Cel-Sci & MK.
    **** That study had ZERO to do with Cel-Sci ****. ****It had ZERO to do with MK****.

    He then INCORRECTLY reports results from the P2 Hungarian clinical trial while completely ignoring the P2 Israeli clinical trial ( The results are published on the JAMA site).

    C assa delights in posting about the 19 patients , which he CLAIMS is really 17.

    Here is the REAL number:
    "Of the *21* LI-treated patients, *19*were assessable.
    Two of the treated patients were enrolled and subsequently confirmed as having anaplastic carcinoma of the uvula and adenocarcinoma of the floor of the mouth, respectively.

    These two patients were administered the full course of therapy, including the administration of the investigational drug, but
    they **were not part of the histopathology and immunohistochemistry analysis because they did not meet the criteria for having OSCC**.

    Is there anyone that can't understand that SIMPLE FACT?

    WILL the FDA EVER re-evaluate the completed P2 from 14 years ago ????
    They will **NEVER** use ANY P2 results for their P3 evaluation.

    c assa also attacked IL.
    There are OVER 700 different types of IL being used in countless clinical trials.
    MANY BILLIONS of dollars is being spent by bio's/pharmas , researchers , scientists .
    AND NOT ONE will listen to c assa and his MINDLESS rants.
    TAKE A HINT!

    Maybe there is a reason???
    Like he has ZERO credibility,& ZERO knowledge.

    Then there is attack on the H&N P3 & nationality.
    He foolishly posts an FDA E5 document that CLEARLY says it's not an issue in the P3.
    He may have deleted his post.

    Anyone & everyone that says anything positive about Cel-Sci, is PROMPTLY ATTACKED, AFTER they post.

    More later.

    Sentiment: Strong Buy

  • Reply to

    Bio goes from 86 CENTS to $261.25

    by yankeesnyc27 Mar 15, 2016 2:20 PM
    yankeesnyc27 yankeesnyc27 Apr 20, 2016 3:57 PM Flag

    RE: BMY.... Has anyone looked at their 10 year chart?
    That 10 year high was 4 months ago.
    Funny how difficult it is to move a $115B stock.
    Contrast that to a mom & pop bio .

    Does anyone realize that CVM , with FDA H&N MK approval could LEAP past BMY share price ?
    BTW: How many patients does the BMY H&N med cure???
    Isn't the answer ,NONE?
    The tumor reduction rate is similar to MK.

    Sentiment: Strong Buy

  • yankeesnyc27 yankeesnyc27 Apr 20, 2016 3:36 PM Flag

    Hey c assa sandra..... "RAMBLING"??? YOU have gone from IMPROPERLY treated inventiv P3 patients to :
    COLD FILL
    BYRON
    $12M
    inventic
    ARBITRATION

    inventiv.... At the rate of their P3 enrollment would have taken 16-17 years to complete.
    The word "BOTCHED" seems to have eluded you.

    SOOO, now we have YOUR invaluable opinion ( from a perpetual PATHOLOGICAL liar ) that inventiv wins the arbitration.

    SOOO, it's OK to take 16-17 years to complete a P3

    It's OK for Cel-Sci to be forced to find another 100-117 H&N P3 patients to "do over", the
    inventiv "BOTCHED" treating of 85%-100% of the patients , in the snail paced P3.

    The inventiv case is SOOO strong , NOT, that they have avoided having the arbitration completed for over TWO years.

    Of course we have c assa 's word the inventiv will win.

    The same c assa that said the tumors always grow back , but somehow, he for to mention he wasn't posting about Cel-SCi NOR MK. A small omission , NOT.

    Then there was his MINDLESS attack on IL.
    BTW: There are OVER 700 different kinds of IL.

    ALLLLL those bio's /pharmas spending $BILLIONS on IL ,when casssa could have told them how stupid they are and how smart, he THINKS he is.

    He forgot to mention MK is NOT IL, it's a patented combination of 14 (?) ingredients.

    Then he attacked the nationality of the H&N P3 patients and even mentioned an FDA ( E5 ?) document , that when read says it didn't apply to Cel-Sci and the H&N P3.

    MORE when I can.

    Sentiment: Strong Buy

  • yankeesnyc27 yankeesnyc27 Apr 20, 2016 1:18 PM Flag

    Still another post from the PATHOLOGICAL liar, c assa sandra.
    Will today's lie stick??

    It doesn't matter , tomorrow , like always there will be another c assa post from the , I'm obsessed with CVM and will continue the onslaught , even it it doesn't make any sense.

    Today ATTACK: "That the first 100 patients in the Multikine trial, the ones where a treatment effect, if any, should now be apparen,t are the very ones ****Geerty is trying to toss out?****

    Could someone , ANYONE provide any VERIFIABLE information that "Geerty" is trying to remove ANY P3 data??

    A judge that has NOTHING to do with Cel-Sci , and has rendered a decision that the Inventiv insurance company is responsible for paying any judgements made in favor of Cel-Sci ( & may have to provide a legal defense ? ).
    That very same judge that said the Inventiv portion of the P3 was "BOTCHED".

    That judge didn't rule that "Geerty" wants to remove any P3 data , did he?

    Cel-Sci is about 86 +% P3 completed and in less than 6 weeks will have less then 10% of patients remaining to be treated.

    MORE TO FOLLOW.

    Sentiment: Strong Buy

  • yankeesnyc27 yankeesnyc27 Apr 19, 2016 7:27 PM Flag

    Is it my imagination ???? Is c assa sandra OBSESSED with every word I post???

    "Only fools and frauds are in this POS, " , then why does c assa continue to post false & LIBELOUS material about a "WORTHLESS" stock???
    What is the value of an FDA approved H&N MK ???

    Would any sane person continue to rant about a worthless stock???
    100% of c assa out is trashing CVM???
    WHY???
    What should investors do ??
    BUY?
    SELL?
    HOLD?

    Maybe c assa is angry due to his DUMPER post today ??

    Sentiment: Strong Buy

  • yankeesnyc27 yankeesnyc27 Apr 19, 2016 7:03 PM Flag

    Why would anyone care what I make or lose on a stock???
    "There is no profit or loss , UNTIL shares are sold.
    Every day is one day closer....

    Sentiment: Strong Buy

  • yankeesnyc27 yankeesnyc27 Apr 19, 2016 7:01 PM Flag

    Speaking of trash.... Will the FDA ever read ONE of your NONSENSE posts???

    Anyone notice ; How people are TRASHED after saying something nice about CVM??

    Sentiment: Strong Buy

  • Reply to

    Multikine is 30-plus years old...

    by johnnycassandra Apr 19, 2016 5:56 PM
    yankeesnyc27 yankeesnyc27 Apr 19, 2016 6:14 PM Flag

    How smart are posters that PERPETUALLY post to "truly delusional" readers?

    The P3 is about 86% completed and shortly will be 90 % completed.

    P.S. c assa sandra has a LONG track record of posting FALSE , MISLEADING AND *****LIBELOUS*** information.

    Why is there an ARMY of ever changing names attacking a "WORTHLESS STOCK"??

    What is the value of a stock with an FDA H&N approval????
    Ya think it's more than 50-60 cents?

    I do, so do all the MANIPULATORS !

    Sentiment: Strong Buy

  • Reply to

    Looks like CEL-SCI has some competition!

    by redleader66 Apr 19, 2016 3:20 PM
    yankeesnyc27 yankeesnyc27 Apr 19, 2016 3:45 PM Flag

    What follows is a small part of the complete article.

    "The list of cancers being taken down by immunotherapy keeps growing" ( title of article)

    "Researchers say these advances suggest the treatment approach is poised to become a critical part of the nation’s anti-cancer strategy."

    "Scientists reported Tuesday on two new studies showing that the medications, which marshal the body’s own immune defenses, are now proving effective against **difficult-to-treat head and neck cancer** and an extremely lethal skin cancer called Merkel cell carcinoma. "

    "The new studies appear to be the first to find that **virus-driven cancers** can be amenable to treatment by immunotherapy"

    "We’re really seeing the fruits of many years of research into what drives cancer and how it interacts with the immune system to defeat it and survive.”

    "The latest findings, as well as ***hundreds of ongoing clinical trials*** across the country, suggest that immunotherapy could be beneficial for more than two dozen kinds of cancer — and maybe many more."

    “This period for immunotherapy is comparable to the 1960s for chemotherapy, when we were just beginning to use it"

    ****Head and neck cancer, a devastating disease that affects the patient’s ability to eat, breathe and talk, can be caused by the human **papillomavirus**, or HPV.****

    Sentiment: Strong Buy

  • Reply to

    Looks like CEL-SCI has some competition!

    by redleader66 Apr 19, 2016 3:20 PM
    yankeesnyc27 yankeesnyc27 Apr 19, 2016 3:27 PM Flag

    The entire post is in today's Washington Post ( & on Yahoo ). It's an important read for all Cel-Sci investors.
    The reporters name is listed.
    Ya think maybe, it would hurt share value to contact the reporter and alert her to MK???

    SOON P3 will be 90% completed.

  • yankeesnyc27 yankeesnyc27 Apr 19, 2016 1:33 PM Flag

    *****" ALL THE NEWS IS PAID FOR IN NEW ISSUED SHARES"*****

    HMMMM.... What would you call someone that runs a business and doesn't accept CASH????

    Could they be be DUMB? STUPID? OR , perhaps BROKE?
    Maybe, THEY think there is something **MORE VALUABLE than CASH**??????

    Suppose they accepted stock , in lieu of cash???
    Would that mean **ALL those stock takers saw stock as being more VALUABLE than cash**????

    How much , can cash appreciate in a year? Two years , etc?
    How much can a stock , that has no current income but, has a potential YEARLY income of $10 BILLION , *****APPRECIATE***** in a year? Two years , etc???
    ALSO: That company has ZERO partners just SHAREHOLDERS ( HINT ) !

    Are there any tax advantages for stock over cash????

    BTW: That very same stock that is accepted in *lieu of cash* can be had by ANY investor for less than HALF a DOLLAR !
    $100= 186 SHARES. $200=373 SHARES. $300= 560 SHARES. $500=934 SHARES. $1,000=1,869 SHARES.

    BTW: The P3 is MORE that 86% completed.

    Every day is one day closer........

    Sentiment: Strong Buy

  • yankeesnyc27 yankeesnyc27 Apr 6, 2016 3:42 PM Flag

    hey mp.... This is from the Cel-Sci web page ,dated 17Nov 15 ,almost 5 months ago.

    "CEL-SCI IS GRANTED A NEW EUROPEAN PATENT ON ITS PHASE 3 INVESTIGATIONAL CANCER IMMUNOTHERAPY MULTIKINE "

    "Vienna, VA, ****November 17, 2015"****-- "CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") announces that it has been granted a European patent on Multikine (Leukocyte Interleukin, Injection), its investigational Phase 3 cancer immunotherapy."
    "The patent, number ***EP 1 753 452 B***, is entitled: A METHOD FOR ALTERING THE CD4/CD8 RATIO AND THE MONONUCLEAR CELLULAR INFILTRATE INTO A TUMOR."

    "The patent is **important because** it recites a **mechanism of action of Multikine by which Multikine changes the type of T cells that enter the tumor microenvironment.**

    "This change results in the tumor becoming **"visible"** to the *immune system*, resulting in a **robust and *sustainable* anti-tumor immune response**.

    P.S. Yes , the article did appear today on PDR , it's a network location.
    However, looking at that article; it links back to Cel-Sci and 17 Nov15.

    Note to MP: As you have found out it is possible to post links , *MINUS* the DOTTTT-COMERCIAL.
    You did that on your youtube post.
    BTW: Thank you for that.

    NOW ,about conway, who does he work for???
    I did search and found nothing. I'm sure my search was at fault.
    I would like to verify/confirm the Conway information.

    R.I.P. ****POISON PILL**** :(

    Sentiment: Strong Buy

  • Reply to

    enrolment after July 20

    by equity_jake Apr 6, 2016 2:01 AM
    yankeesnyc27 yankeesnyc27 Apr 6, 2016 3:08 AM Flag

    hey eq... Sorry, your numbers are correct mine should have read 4-5 Aug.
    So far, there has been no mention by the FDA . RE: inventiv "do-over."

    784 could be reached before the end of this month.

    There has also been reports of FDA to speed up approvals. To as quickly as 60 days.
    ALSO reports of compassionate approvals on a per patient basis ( sorry , i forget the exact wording. )

    Look at Yahoo health on a daily basis. I think it was there a few days ago.

    "The end is near" Kim Kardashian :)

    Sentiment: Strong Buy

  • yankeesnyc27 yankeesnyc27 Apr 6, 2016 2:44 AM Flag

    This is from the SEC filed IPO document : "A hearing is currently scheduled to begin in September 2016. **No assessment** can be made **at this time** as to the **likely outcome** of this matter. Accordingly, no provision has been recorded as no loss is considered probable. "

    Does that mean inventiv expects the insurer to bear the full brunt of any adverse ruling ??

    NOTE 12: "Other Matters "
    "The Company is subject to lawsuits, investigations and claims arising out of the conduct of its business, including those related to commercial transactions, contracts, government regulation and employment matters. Certain claims, suits and complaints **have been filed or are pending against the Company**. The Company does not believe that the **outcome of any legal proceedings, if decided adversely** to its interests would have a ***material adverse** effect on our business, financial condition or results of operations. "
    F-30

    Form S-1 - General form for registration of securities under the Securities Act of 1933
    SEC Accession No. 0001193125-16-530932

    Filing Date
    2016-04-05
    Accepted
    2016-04-05 17:19:26

    SEC, a government "location".....

    /Archives/edgar/data/1497350/000119312516530932/0001193125-16-530932-index.htm

    Sentiment: Strong Buy

  • Reply to

    enrolment after July 20

    by equity_jake Apr 6, 2016 2:01 AM
    yankeesnyc27 yankeesnyc27 Apr 6, 2016 2:22 AM Flag

    hey eq.... using 30 patients per month the 880 will reached on Jul 4-5 2016.

    If 784 is used the P3 will be reached NEXT month.
    IMO: 298 deaths has been set by the FDA.

    Didn't the inventiv/insurer, judge refer to the inventiv work as "BOTCHED"?

    Now that the insurer is stuck with a large possible loss; would they expect to continue as the inventiv insurer??
    IMO : The answer is no.... Would that insurer care about inventivs, reputation???
    I think not.
    Lets see.... Take about 28 months to treat 117 patients ( average 4.2 patients per month ) , AND 85- 100% of THEIR P3 patients need to be redone/replaced , & take about 17 + YEARS to complete the P3; VS.about 25 months for ERGOMED.

    With the completed P3 AND FDA H&N MK approval = $10 B in YEARLY sales = in EPS?? PPS ??

    A lot more the the current price .

    Sentiment: Strong Buy

  • yankeesnyc27 yankeesnyc27 Apr 5, 2016 4:03 PM Flag

    It['s relevant because YOU said so.....How much does ERGOMED have in the pot???

    The FDA does not care, why should ANYONE else?

    No one on this M/B puts ONE penny into Cel-Sci's pocket

    Sentiment: Strong Buy

  • yankeesnyc27 yankeesnyc27 Apr 5, 2016 3:33 PM Flag

    And Is that relevant to the LATE stage P3 ???
    Start some more threads; post about the University of Turin and their NON FDA clinical that did NOT test MK.
    Pretend that that IL & MK is one and the same.
    Patent offices in 9 counties say different .
    There are OVER 700 different kinds of IL ......all those silly DOCTORS wasting their time & money because c assa a M/B said they are ALL wrong.

    Sentiment: Strong Buy

  • Reply to

    Vanguard increased holdings in Q4

    by mpj520 Apr 5, 2016 12:07 PM
    yankeesnyc27 yankeesnyc27 Apr 5, 2016 3:18 PM Flag

    So says c assa sandra the PERPETUAL poster of false & LIBELOUS information.
    Isn't Park a Billion dollar hedge fund??
    What % of CVM does Park hold???
    ENOUGH to double the # of I.O. shares held.
    Does the FDA evaluate medications OR institutional Ownership???

    Sentiment: Strong Buy

  • Reply to

    H&N cancer trials at Hopkins

    by johnnycassandra Apr 5, 2016 1:51 PM
    yankeesnyc27 yankeesnyc27 Apr 5, 2016 3:15 PM Flag

    Is the P3, the Westminster dog show, where pedigree is important???
    Or are H&N patients from MANY nations being evaluated on MK + SOC vs. SOC??

    The sun doesn't rise or set on JH, or any other hospital ,etc.
    The FDA will determine the fate of MK , NOT JH , or c assa .

    I trust the FDA and NOT the perpetual poster of FALSE & LIBELOUS information to designed MANUFACTURE cheap FEAR shares with EXISTING shareholders are buying.

CVM
0.5592-0.0093(-1.64%)Apr 28 4:00 PMEDT